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ORIGINAL  ARTICLE
Background: We conducted an open trial to evaluate the efficacy of repetitive transcranial magnetic stimulation
(rTMS) in medication-resistant depression. This is the first study in Taiwan of rTMS for the treatment of depression.
Methods: A 2-week regimen of rTMS (100% of motor threshold, 5 Hz, 8 sec, 40 trains/20 min/day, 10 weekdays)
applied to the left dorsolateral prefrontal cortex was administered to 11 patients with medication-resistant depression.
Results: Ten subjects completed 2 weeks’ treatment with rTMS. Scores on the 21-item Hamilton Depression Rating
Scale (HAM-D21) and Beck Depression Inventory decreased by 48% and 28%, respectively. Five patients were clinical
responders (* 50% reduction in HAM-D21 score): 2 of these were in complete remission (HAM-D21 score ) 7). Five
patients were less responsive: 2 of these were partial responders (20–49% reduction in HAM-D21 score), whereas
3 did not improve. Younger versus older age was identified as a potential predictor of response to rTMS used as
add-on therapy.
Conclusion: Our preliminary results indicate that rTMS can improve mood in patients with medication-resistant
depression, and can also potentially replace electroconvulsive therapy for certain types of medication-resistant
depression. Future double-blind, placebo-controlled trials of rTMS are warranted. [J Chin Med Assoc 2005;68(5):
210–215]
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Introduction
In the United States, the widespread prevalence of
depression was determined in a large national survey
by Kessler et al.1 The lifetime risk of major depression
was estimated to be as high as 34%, and this estimate
rose to 50% when bipolar and chronic minor depressions
were included.1 While most depressive symptoms are
eliminated by current pharmacologic treatments, as
many as 50–60% of patients have incomplete recovery
or significant adverse effects.2 Nonpharmacologic
methods for alleviating depression have recently
*Correspondence to: Dr. Tung-Ping Su, Department of Psychiatry, Taipei Veterans General Hospital, 201,
Section 2, Shih-Pai Road, Taipei 112, Taiwan, R.O.C.
E-mail: tpsu@vghtpe.gov.tw • Received: August 30, 2004 • Accepted: December 1, 2004
received renewed attention. Electroconvulsive therapy
(ECT) is the most effective nonpharmacologic
treatment, particularly for refractory depression.3
Although the antidepressant mechanisms of ECT are
unknown, recent data indicate that production of a
generalized convulsion is not sufficient for treating
depression.4–7 However, the effect of the ECT seizure
on regional brain function is important in determining
the therapeutic benefit.4,5 These data are consistent
with evidence from functional neuroimaging studies
that have implicated prefrontal, temporal, and limbic
structures in depression.6
©2005 Elsevier. All rights reserved.
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rTMS for treating depression
Recently, transcranial magnetic stimulation (TMS)
has been developed as a novel tool for potential anti-
depressant treatment that, unlike ECT, does not
cause a seizure or require anesthesia.7 TMS is a non-
invasive method of influencing regional electrical
activity in the brain with safe, subconvulsive stimu-
lation, and with little or no pain. A powerful but local
magnetic field is generated by passing brief, powerful
electrical current through a conducting coil placed
on the scalp. The rapidly alternating magnetic field
passes unhindered through the skull and produces
weaker, focal electrical currents, thereby activating
neurons in the brain.8 Subjects usually notice no
adverse effects, except for occasional mild headache
and discomfort at the site of stimulation. Recent
technologic advances led to the development of
magnetic stimulators that can repeatedly stimulate
faster than 1 cycle of frequency per second. Repeated
magnetic stimulation at * 1 Hz is, by convention,
called “repetitive transcranial magnetic stimulation”
(rTMS). The results of some positron emission
tomography (PET) studies suggested that stimulation
at different frequencies may have divergent and even
opposite effects on neuronal activity.9,10 High
frequency rTMS may enhance, while low frequency
rTMS may inhibit, cortical excitability.
George and Wassermann11 hypothesized, based
on the following evidence, that selective subconvul-
sive rTMS over key brain regions might have an
antidepressant effect: abnormalities of the left
prefrontal cortex were found in functional neuro-
imaging studies of depression; changes in pre-
frontal cortex activity predicted response to ECT;
and patients with left prefrontal strokes had an
increased risk of depression.4,12 In subsequent studies,
George et al13–15 found a striking antidepressant effect
for rTMS over the left prefrontal cortex in an open
trial,13 a double-blind crossover trial,14 and a placebo-
controlled study.15 All these experimental results
indicated that the use of high-frequency stimuli over
the left dorsal prefrontal cortex had a significant
antidepressant effect.
The current study was designed as a 2-week, open
trial to confirm the significant antidepressant efficacy
of rTMS in Chinese patients with refractory depression.
Additionally, some reports16,17 showed that older
depressed patients may respond less well to rTMS. In
1 of our previous studies,18 the percentage shortening
of choice reaction time induced by rTMS was negative-
ly correlated with age in healthy individuals; in the
current trial, we therefore examined whether age dif-
ferences might influence the antidepressant efficacy
of rTMS.
Methods
Study participants
Eleven patients with a major or bipolar depressive
episode diagnosed by Mini  Internat ional
Neuropsychiatric Interview19 and meeting DSM-IV
criteria20 were enrolled in a 2-week, open trial of
rTMS. After receiving a full explanation of the
procedure, all subjects signed a consent form. The
study protocol was approved by the Institutional
Review Board of Taipei Veterans General Hospital
and the National Health Department of Taiwan.
All study participants had medication-resistant
depression, and had failed to respond to at least 2 trials
of antidepressant drugs over a 3-month period before
rTMS. The severity of depression at entry was above
moderate (i.e. 21-item Hamilton Depression Rating
Scale21 [HAM-D21] score > 18). Four subjects (numbers
2, 4, 7 and 9) were inpatients during the trial. For
ethical reasons, all patients were allowed to continue
their unsuccessful antidepressant medications during
the 2-week course of rTMS: serotonin-noradrenaline
reuptake inhibitors (venlafaxine [n = 4], mirtazapine
[1]); or selective serotonin reuptake inhibitors
(paroxetine [2], fluoxetine [1], citalopram [1], ser-
traline [1], fluvoxamine [1]). One patient (number
8) took antidepressant medication in combination
with an antipsychotic (olanzapine; Table 1). No
medication changes were allowed for 2 weeks before,
or during, rTMS.
Patients were excluded from the study for the
following reasons: physical and neurologic abnor-
malities; implanted pacemakers; a substantial risk of
suicide during the trial; a history of seizures, major
head trauma or psychotic symptoms. No patients had
a history of ECT. Ten patients completed the rTMS
regimen, and 1 dropped out because of intolerable
headache induced by rTMS.
TMS procedure
A trained psychiatrist (CCH) performed rTMS using
a Magstim® super-rapid magnetic stimulator (Magstim
Co Ltd, Whitland, Wales, UK), with 4 booster modules
equipped with a 70-mm, air-cooled, figure-of-8-shaped
coil. The coil was held with the handle posterior and
oriented sagittally. Subjects were seated upright in a
comfortable chair with eyes open, and foam earplugs
were used during rTMS to diminish noise from the
discharging coil.
At the initial treatment visit, patients had their
motor threshold (MT) determined at rest in the
contralateral (right) abductor pollicus brevis (APB)
muscle, as described previously.22 The stimulation site
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on the left dorsolateral prefrontal cortex was defined as
the region 5 cm rostral and in a parasagittal plane from
the site of maximal APB stimulation. This method of
locating the stimulation site has been used in other
rTMS studies of depression.15,23 Each day, subjects
were asked about events that could have changed the
MT (medications, sleep deprivation, etc.), the MT was
quickly rechecked, and the daily dose was adjusted
accordingly. The re-calculated MT never changed
more than 5% from baseline.
Subjects received 20 minutes of rTMS each weekday
for 10 sessions during a 2-week period. They were
given 40 trains in each session, with each train of 5 Hz
(8 seconds on and 22 seconds off) at 100% of MT. In
other words, 1,600 pulses per session and a total of
16,000 pulses were delivered throughout the 10-
session treatment schedule.
Ratings and response classification
The severity of depression at baseline and at the end of
each week was rated by a psychiatrist (TPS) using the
HAM-D21, and by patients using the Beck Depression
Inventory (BDI).24 Clinical response to rTMS was
evaluated by calculating the percentage improvement
in HAM-D21 scores from baseline to the end of
treatment: responders had a reduction of * 50%;
partial responders a reduction of 20–49%; and non-
responders a reduction of < 20%.
Statistical analysis
HAM-D21 and BDI score differences between study
entry and the end of treatment were compared by the
Wilcoxon matched-pairs signed-ranks test, and the
relationship between age and rTMS-induced changes
in HAM-D21 scores was obtained by Pearson’s product-
moment correlation test. In seeking predictors of
clinical responsiveness to rTMS, characteristics such as
demographic variables and clinical features at study
entry were compared between responders and non-
responders using the non-parametric Wilcoxon test,
or the non-parametric Chi-squared test. All statistical
tests were 2-sided, and used the 5% level of significance.
Results
Demographic data and depression scores over time are
shown in Table 1. The rTMS regimen was generally
well tolerated by all except 1 patient (number 6) who
dropped out in the third rTMS session because of
intolerable headache; this patient required acetami-
nophen to reduce her headache. Three patients
(numbers 2, 4 and 9) reported mild headache on a few
occasions immediately after rTMS; these headaches
were relieved by a short period of rest. No patients
reported problems with memory or attention, and
there were no seizures (a possible adverse effect of
rTMS).
Significant decreases in HAM-D21 score (Z = –2.666,
Nties = 9, p = 0.008) and BDI score (Z = –2.807,
Nties = 10, p = 0.005) were observed with rTMS. The
2-week treatment schedule produced overall decreases
Table 1. Demographics and depression scores for 11 patients receiving repetitive transcranial magnetic stimulation
Score on HAM-D21 Score on BDI
Patient Gender Age Diagnosis Antidepressant Baseline End of End of Baseline End of End of Responder
(yr) therapy and daily dose week 1 week 2 week 1 week 2
1 F 32 MDD Fluvoxamine 150 mg 30 12 9 36 23 19 Yes
2 F 31 MDD Venlafaxine 300 mg 38 20 13 50 37 37 Yes
3 F 50 MDD Venlafaxine 300 mg 30 30 30 50 37 44 No
4 M 47 MDD Venlafaxine 300 mg 22 9 4 27 25 12 Yes
5 F 39 MDD Sertraline 100 mg 22 12 12 10 7 2 Partial
6* F 46 MDD Paroxetine 20 mg 23 – – 29 – – –
7 M 33 MDD Paroxetine 40 mg 31 4 4 14 2 8 Yes
8 M 21 MDD Fluoxetine 20 mg, 24 15 10 18 13 13 Yes
olanzapine 10 mg
9 F 42 MDD Mirtazapine 30 mg 34 26 22 59 56 33 Partial
10 F 65 MDD Citalopram 40 mg 19 19 17 47 46 45 No
11 F 40 BD2 Venlafaxine 150 mg 23 20 20 32 27 30 No
Mean – 40.6 ( – – 26.9 ( 6.0 16.7 ( 7.9 14.1 ( 8.2 33.8 ( 27.3 ( 24.3 ( –
(  SD 11.7 16.2 17.1 15.5
*Dropped out because of headache. BD2 = bipolar disorder type II; BDI = Beck Depression Inventory; HAM-D21 = 21-item Hamilton Depression
Rating Scale; MDD = major depressive disorder; SD = standard deviation.
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in HAM-D21 score of 48% and in BDI score of 28%.
Five patients (numbers 1, 2, 4, 7 and 8) were clinical
responders, and 2 of these (numbers 4 and 7) were in
complete remission (HAM-D21 score ) 7).25 Another
5 patients were less responsive: 2 of these (numbers 5
and 9) were partial responders, whereas 3 (numbers 3,
10, and 11) were non-responders. In total, 7 of 10
patients (70%) experienced symptom amelioration
after 2 weeks of rTMS treatment. Nevertheless, a trend
was observed towards a negative association between
percentage decrease in HAM-D21 score and increase in
patient age in individuals subjected to rTMS (n = 10,
r = –0.59, p = 0.072).
In the search for predictors of clinical outcome, a
significant age difference was noted between respond-
ers and non-responders (Z = –1.984, p = 0.047), i.e.
responders were significantly younger than non-
responders (mean age 32.8 vs 47.2 years). However,
there were no significant differences in terms of age at
disease onset, gender, types of depression (unipolar vs
bipolar), number of previous depressive episodes,
duration of current episode, and depression and anxiety
scores at study entry. Conversely, changes in HAM-
D21 scores from baseline to weeks 1 and 2 were
significant in responders (Z = –2.417, p = 0.016; and
Z = –2.611, p = 0.008, respectively), but not in non-
responders (Figure 1).
Discussion
rTMS for the treatment of medication-resistant
depression is one of the major advances in modern
psychiatry, and this is the first study examining the
efficacy of rTMS over the left prefrontal cortex in
Chinese patients with such depression. The results are
comparable with previous reports from Western
countries,15,23 but demonstrate a robust effect for
rTMS in ameliorating depression in Chinese patients
with medication-resistant depression.
Table 2 shows a comparison of stimulation
parameters, patient diagnoses, concomitant anti-
depressant therapy, and response rates, between our
study and 3 others.15,26,27 The same parameters and
total pulses were used in our study and 2 others:15,27
our response rate was identical to that in 1 trial (48%),15
but markedly greater than that in the other (48% vs
25%),27 despite the latter trial27 using a higher intensity
of rTMS (MT 110% vs 100%). Shajahan et al26 used
only about 1-third of the total number of pulses
(5,000 vs 16,000 pulses) and a lower MT (80% vs
100%) than in our study, but reported the same clinical
response rate (48%) as in our trial and in that conducted
by George et al.15 Clearly, the applied stimulus does not
Table 2. Comparison of repetitive transcranial magnetic stimulation parameters, patient diagnoses, medication status and
response rates in 4 studies
Present study
George et al15 Shajahan et al26 Nahas et al27
(Huang et al)
Frequency (Hz) 5 5 5 5
Train duration (sec) 8 8 4 8
Trains per session 40 40 20 40
Total number of pulses 16,000 16,000 5,000 16,000
Intensity (% of MT) 100 100 80 110
Site of stimulation LDLPFC LDLPFC LDLPFC LDLPFC
Diagnosis Unipolar depression Unipolar depression Unipolar depression Bipolar depression
(most) (most)
Medication resistant Yes Yes No No
Concomitant antidepressant therapy Yes No Yes No
Clinical improvement (% decrease in
  HAM-D21 score from baseline)
48 48 48 25
HAM-D21 = 21-item Hamilton Depression Rating Scale; LDLPFC = left dorsolateral prefrontal cortex; MT = motor threshold.
Figure 1. Mean changes in Hamilton Depression Rating Scale
score from baseline to the end of the trial. Responder versus non-
responder: *p < 0.05; †p < 0.01.
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correlate absolutely with clinical efficacy. On the other
hand, depressed patients in Shajahan et al’s study,26
unlike the treatment-resistant patients in George et
al’s15 and our studies, might be more responsive to less
intensive treatment. The lower clinical response rate in
the study conducted by Nahas et al27 than in our study
and the other 2 trials, despite the greater intensity of
treatment, may have resulted from the diagnosis of
bipolar rather than unipolar depression. In our study,
rTMS patients received concomitant antidepressant
medication, whereas patients in the study conducted by
George et al15 did not. Whether such concomitant
therapy confounds the clinical outcome of rTMS remains
unclear. Indeed, rTMS plus antidepressant therapy may
provide a greater benefit than rTMS alone, or the
heterogeneity of antidepressant medication may interact
negatively with rTMS.28 These potential confounding
factors may explain the discrepant results for rTMS in
the abovementioned studies.
Corresponding with previous reports,4,22 we ob-
served a trend towards a negative correlation between
age and decrease in HAM-D21 score, indicating that
younger depressed patients respond better to brain
stimulation than their older counterparts. Imaging
studies have shown prefrontal cortex atrophy in older
depressed patients.23,24 The degree of brain atrophy,
particularly in the prefrontal lobe, might explain the
relatively reduced antidepressant response to rTMS in
older depressed patients.16 However, our elderly
patients were aged 50–65 years, and not > 65 years as
usually defined. Therefore, further investigations using
larger sample sizes will help to determine whether
reduced responses to rTMS are associated directly
with patient age (i.e. > 50 or > 65 years), or with the
degree of brain atrophy regardless of patient age.
In this study, we also observed a significant reduction
in HAM-D21 scores from the first week of treatment
and into the second week of the trial. This finding is
supported by the report of Grunhaus et al,29 in which
a positive response to rTMS was evident by day 3 of
treatment. Since the sample size was small in these 2
studies, further investigation of these findings is needed.
There were several methodologic limitations in
our study. First, the sample size was too small to
validate the general application of rTMS in depressed
patients. Second, our study was an open trial; therefore,
a placebo response, resulting from factors such as daily
contact, support for rTMS, and popular beliefs
concerning the effects of magnetism, cannot be ruled
out, even though, as George et al13 mentioned, placebo
responses would be unexpected in patients with
medication-resistant depression. The psychiatrist who
rated responses (TPS) was totally blinded to the
performance of rTMS throughout the treatment
sessions. This, together with the unlikelihood of a
marked placebo response, may have reduced some of
the potential study bias. Third, our study had an add-
on design, such that concomitant antidepressant
medication may have confounded the results of rTMS
treatment. To resolve the above issues, a double-blind
study with medication-free patients, either refractory
or non-refractory to pharmacologic treatment, is
recommended.
Grunhaus et al30 reported that the efficacy of rTMS
is comparable to that of ECT in non-delusional major
depression, but with fewer and/or less intense adverse
effects, e.g. no pain, no requirement for anesthesia,
no need for coupled seizure induction, and fewer
risks and cognitive impairments. Although the anti-
depressant mechanisms of rTMS action remain
unclear, the need to induce generalized convulsion
(as is thought to be critical for ECT efficacy) can be
questioned. Also relevant is whether subconvulsive
rTMS can replace ECT for difficult-to-treat depres-
sion, and whether it may be more beneficial than
ECT. Some major discrepancies among rTMS studies
indicate that treatment parameters (intensity, dura-
tion, pulses, and frequency) have not been opti-
mized.7 The use of optimal treatment parameters may
increase and sustain the response to rTMS.
In conclusion, our preliminary findings support
the notion that rTMS may improve mood in patients
with medication-resistant depression in Taiwan.
However, these findings require confirmation in a
double-blind, placebo-controlled study. How to
optimize rTMS treatment, with appropriate changes
in parameters, particularly in the Chinese population,
also needs to be explored.
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